Skip to main content
Quest Diagnostics

Toxic Epidermal Necrolysis-Like Linear IgA Bullous Dermatosis as a Manifestation of Multiple Drug Hypersensitivity in the Setting of Drug Reaction With Eosinophilia and Systemic Symptoms

Toxic Epidermal Necrolysis-Like Linear IgA Bullous Dermatosis as a Manifestation of Multiple Drug Hypersensitivity in the Setting of Drug Reaction With Eosinophilia and Systemic Symptoms

Authors: Stratman S, Zhou L, Kim RH, Phelps RG, Glickman J, Mikhaylov D, Wu J, El-Kashlan N, Rivera-Oyola R, Adalsteinsson JA, Levoska MA, Gulati N

Citation: JAAD Case Rep. 2024 Apr 27;49:36-39. doi: 10.1016/j.jdcr.2024.04.028. eCollection 2024 Jul.

Specialties: Dermatology, Immunology, Toxicology

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Publication
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
Publication
Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.